Earnings · US stocks

ArriVent BioPharma, Inc. (AVBP) earnings

ArriVent BioPharma, Inc. published its quarterly report on 2026-11-09. The stock moved -7.70% in the 3 trading days after the report.

Report
quarterly report
Published
2026-11-09
Result
Bad / loss
Open earnings in Wave Radar

Stock move after the report

Trading days from the first tradeable session; dividend-adjusted. "vs index" is the excess return over CSI 300 for A-shares.

AfterReturnvs index
1 day-4.73%—
3 days-7.70%—
7 days-23.02%—

Report history

Over the last 8 reports, EPS beat the consensus estimate in 3 of them. The stock rose in the 3 trading days after 3 of 8 reports (average -2.11%).

PublishedEPSEPS surprise3 days after30 days after30d vs index
2026-11-09-0.81+23.68%-7.70%——
2026-08-12-1.05-6.73%-7.79%-4.32%-3.64%
2026-05-11-0.96-7.40%-2.07%+10.34%+11.16%
2026-03-05-0.78+7.69%+0.32%+17.39%+13.15%
2025-11-10-0.83-6.02%+11.94%+24.13%+22.07%
2025-08-11-0.90-26.51%+0.17%+3.50%-1.15%
2025-05-12-1.90-175.36%-6.95%+14.69%+7.17%
2025-03-03-0.61+21.93%-4.83%-23.13%-12.99%

The last 8 reported quarters. Moves count trading days from the first tradeable session after the report; "30d vs index" is the excess return over the market index.

Stock valuations: AVBP

How to read this

Results are grouped by reported profit growth (great, good, neutral, bad or a loss). For China A-shares the quality score starts at 100 and loses points for gaps a reader can check: operating cash falling short of profit, receivables or inventory outrunning revenue, profit that rests on one-off items or subsidies, heavy goodwill and a qualified audit opinion.

Figures are generated automatically from Wave Radar's published market data and refresh after each market close.